Multiple Sclerosis. Everything you need to know

On December 29, 1972, the captain and first officer of Eastern Airlines Flight EA-401 spent nine consecutive minutes trying to figure out why a tiny green nose-gear indicator light wouldn’t turn on. They yelled at each other, twisted the lightbulb, argued, called maintenance, and at some point, someone accidentally bumped the yoke. This bumped the autopilot out of altitude-hold mode, quietly drifting the aircraft off course. The plane crashed straight into the Florida Everglades, killing 101 out of 176 people on board—solely because the crew fixated on a single blinking bulb and trusted their automated instruments over reality. The cockpit of an aircraft that spent 9 minutes falling into a swamp held three highly qualified professionals, and all of them chose to trust the computer over their own senses. I urge you to look this up yourself—unfortunately, the "EA-401 crash in the Everglades" is a matter of historical fact.

Why bring this up? Automation is fantastic, but only if the system is structurally incapable of making mistakes. How often do automated systems fail? Early Tesla autoplots regularly plowed into parked vehicles. In 2003, an American Patriot missile battery operating in fully automated mode misidentified a British Tornado fighter jet as a hostile target and blew it out of the sky, killing the pilot and navigator. In 2010, high-frequency trading bots triggered a flash crash on the US stock market based on a false data loop—the market hemorrhaged billions in minutes. In 2020, Medtronic’s automated insulin delivery systems started glitching, throwing patients worldwide into severe hypo- or hyperglycemia. In every single instance, a standalone, isolated calibration error transformed into a systemic catastrophe because human operators stopped cross-checking the machines. With MS diagnostics via MRI, the situation turned out even worse: the calibration error was hardcoded into the standard operating procedure, creating a dangerous illusion of a stable and flawless diagnostic grid.

The contrast agents used in MRI scans are almost entirely built on compounds of gadolinium—a heavy, paramagnetic metal. Their actual job description has nothing to do with "detecting multiple sclerosis," "showing demyelination," or "measuring how sick a patient is." Gadolinium’s actual role is far more mundane: contrast enhancement simply maps zones where the blood-brain barrier has been structurally compromised. When the barrier inflames and turns porous—which happens during MS, brain tumors, infections, physical trauma, and an array of other pathologies—gadolinium molecules leak out into the brain tissue, making those spots burn bright on T1-weighted scans.

A structural breach of the blood-brain barrier occurs across a massive spectrum of conditions—strokes, angiomas, vasogenic edema, vasculitis, trauma, and post-traumatic inflammation. You see the exact same leaks in other autoimmune brain conditions, like systemic lupus erythematosus, sarcoidosis, and Behcet's disease. Furthermore, contrast-accumulating lesions are classic markers for radiation necrosis, post-surgical artifacts, the active phase of progressive multifocal leukoencephalopathy, and various granulomatous processes. Bottom line: bright spots on an MRI screen do not "show multiple sclerosis" and do not confirm a diagnosis. Contrast merely flags a leaky brain barrier, which can be caused by dozens of entirely distinct diseases.

The statistical probability that burning MRI lesions are genuinely tied to multiple sclerosis depends entirely on the clinical context: according to PubMed data, in specialized neurological centers auditing patients with high clinical suspicion of MS, about 50% to 70% of these hotspots are indeed the byproduct of demyelination. In the general population undergoing standard, routine scans, that figure plummets to 10–20%. This is exactly why the mere presence of lesions means nothing; their value hinges entirely on how they map against the total clinical profile.

The healthcare grid, like any massive bureaucratic machine, always moves toward equilibrium—not because it leads to objective truth, but because it streamlines standard operating procedures. When an MRI display throws up a picture full of white spots and a doctor faces a patient with vague, matching complaints, the path of least resistance is to write an equation: "burning lesions = multiple sclerosis." It’s faster, simpler, cleaner, and most importantly, it spares the physician from diving into complex differential diagnosis. Systems balance themselves through these exact shortcuts: an overworked doctor, buried under regulatory metrics and endless charts, stops hunting for absolute truth and settles for a functional compromise. The patient arrives demanding a label, and the presence of glowing spots allows the physician to stop treating MS as a rigorous "diagnosis of exclusion" and instead deploy it as a "catch-all label."

This is one of the foundational paragraphs of this book: if your diagnosis was slapped on based on a random MRI scan you were sent to after a brief, temporary bout of weird symptoms, and sclerosis hasn't bothered you once in the years since, you need to stop and think. No, your health isn't holding because "the interferon is working"—it is entirely possible that you never had multiple sclerosis in the first place. Yes, that is a quite possible—even if the diagnosis came from a doctor you trust unconditionally.

The misdiagnosis of multiple sclerosis is a shockingly common event: for example, in 2019, Marwa Kaisey and Nancy Sicotte tracked 241 labeled MS patients in the US, and discovered the diagnosis was flat-out wrong in 18% of cases—that’s 43 real people. It’s crucial to understand that the researchers only overturned a diagnosis when they were 100% certain it was completely bogus; how many borderline cases of overdiagnosis Kaisey and Sicotte missed is something we will unfortunately never know. What did the investigators expose? First and foremost, they proved that when these bogus labels were minted, the lumbar puncture was systematically ignored: it was either never performed at all, or its negative result was tossed into the trash as "non-informative."

On "Non-Informative" Lumbar Punctures

As you have already realized, multiple sclerosis is surrounded on all sides by deep-seated misconceptions, but nowhere does this diagnostic confusion manifest as clearly as in the analysis of cerebrospinal fluid. This is where the main diagnostic bottleneck lives—overgrown, tangled, and multi-layered. I will try to lay it out so that you can actually understand it, which means I will simplify a few things and use a couple of non-ideal analogies. It won't be effortless, but if you look at it closely, a lot of light will be shed on the myths surrounding the lumbar puncture.

To start, every single one of us carries cerebrospinal fluid—CSF. It bathes the brain and spinal cord, and it is structurally insulated from the rest of the body by a specialized filter: the blood-brain barrier. If the barrier gets damaged and begins letting background noise through, it is always a reason to investigate, but it is far from an exclusive marker for MS. A breach in the barrier can be triggered by absolutely anything—infections, physical trauma, localized inflammation, and a massive spectrum of autoimmune conditions.

When the blood-brain barrier is compromised, lymphocytes drift into the CSF. Don't panic—in and of itself, this isn't particularly dangerous. White blood cells are found in the spinal fluid of perfectly healthy people too. Most of the time, they are simply doing their standard janitorial work: hunting for viruses, bacteria, cellular debris, and other junk. After a while, the barrier patches itself up, and the situation returns to baseline—including on your MRI scans. "Burning lesions" appear precisely because of a breached barrier, and as soon as it heals, they dim or stop glowing altogether.

A single microliter of blood holds anywhere from 1,000 to 4,000 lymphocytes; a single liter holds 1 to 4 billion; and the entire bloodstream carries between 5 and 20 billion. This brings us to another massive misconception: lymphocytes are called blood cells, but the vast majority of them live completely outside the blood. The bulk of the population is dug into the lymph nodes, the spleen, the thymus, mucous membranes, and other strategic hubs of the immune grid. The total number of lymphocytes in the human body is estimated between 1 and 2 trillion, making the bloodstream just a tiny fraction of their massive collective force. During an active infection, the body can ramp up production exponentially through clonal division, causing their numbers to surge in a flash.

How often are defective lymphocytes manufactured? Constantly. But normally, they are wiped out immediately through built-in security protocols that force a rogue cell to commit cellular hara-kiri. Sometimes, however, a flawed T-cell slips through every layer of defense, survives, and takes up residence in a lymph node—becoming a ticking time bomb for an autoimmune reaction. If that T-cell subsequently manages to force its way into the brain tissue and mistakes myelin for an invader, it sounds a chemical siren and calls for backup. Up to a quarter of that backup force is made up of B-lymphocytes, which soon mutate into plasma cells upon arrival.

How many plasma cells actually set up antibody-manufacturing hubs inside the brain tissue of MS patients? Anywhere from a few hundred to several thousand, and they typically descend from just a few dozen clonal lines of B-lymphocytes. This does not mean only a few dozen physical cells are participating in the firefight; rather, it refers to the distinct variants of IgG antibodies—the specific configurations of the BCR receptors on the B-cells that breached the brain. Each of these antibody profiles can be printed by thousands of descendants of a single root B-cell, since B-lymphocytes multiply aggressively, scaling up their immunoglobulin assembly lines. Thus, while the number of distinct clones is discrete, the intensity of their manufacturing output can scale massively. The numbers here are staggering: a single standalone plasma cell can pump out roughly 2,000 antibodies every single second.

The average adult body carries about 150 ml of cerebrospinal fluid. During a standard lumbar puncture, doctors draw roughly 10 ml—about 6% of the total volume, which is drastically higher than the 0.1–0.2% sample taken for a routine blood test. Isolating the specific antibody synthesis profile requires only 2 to 3 ml; the rest goes to cytological, biochemical, and infectious panels. The real bottleneck of the spinal tap lies elsewhere: CSF requires exceptionally delicate handling and rapid transport. Even at the correct temperature, prolonged transit times trigger the breakdown of blood cells caught in the fluid. Outside a living organism, these cells die rapidly; their internal protein structures burst outward, clotting the test gel and rendering the result completely unreadable. By the way, don't sweat the 6% loss: your brain replenishes CSF continuously and rapidly, manufacturing about half a liter of this fluid every single day.

Now, let's look at the test itself. To measure how many B-cell clones are printing antibodies and tracking their manufacturing speed, we have to sort them out somehow. Laboratories use a method called isoelectric focusing—a specialized technique that separates immunoglobulins based on their isoelectric point, which is the exact pH level where the antibody's electrical charge drops to zero. Essentially, the CSF is poured onto a gel matrix with a built-in pH gradient. Antibodies from different clonal families lose their charge at different acidity levels, settling across the gel in visible "oligoclonal bands" that map back to specific B-cell lineages. Every single band is the footprint of a distinct clan of autoimmune hunters printing antibodies modeled on their progenitor's receptor.

I think it's time to pause and roll out the analogy I promised at the start. Picture the CSF as an active combat zone, and the activated autoimmune B-lymphocytes as soldiers armed with machine guns. Each soldier's gun is loaded with a unique color of tracer ammunition. These B-cells can multiply by splitting, but the guns and tracers carried by their copies remain identical to the original, which means the spent cartridges—the antibodies—left on the battlefield carry the exact same color signature. If you collect and sort these cartridges across different sectors of the field, you can calculate exactly how aggressively a specific soldier and his clone platoon were firing their weapons.

Before drawing any macro conclusions, it's worth noting that in about 10% of cases, the biological sample degrades and fails to throw up clean, visible bands. This is almost always a logistics issue: the sample hits the lab spoiled because lymphocytes ruptured in transit, bleeding their internal protein noise into the fluid and clogging the gel, making the matrix unreadable. Pay close attention: this happens in no more than 10% of cases, yet this exact variable is why so many neurologists repeat the mantra that "the spinal tap is non-informative." The reality is uglier: the majority of them have never bothered to look into how the lab analysis is actually conducted; they simply echo a position widely accepted within their professional echo chamber. For context: routine tests for streptococcus, staphylococcus, herpes, chlamydia, and tuberculosis show an identical false-negative rate. Have you ever heard a doctor claim that a tuberculosis test is "non-informative"?

At this point, we need to clarify a highly counterintuitive fact: the antibodies discovered in the CSF are almost never targeted at myelin proteins. Oligoclonal bands do not show how many layers of nerve insulation are under active assault—they merely flag the presence of B-cells inside the brain tissue actively driving an autoimmune crossfire. The primary destructive role of B-cells in the pathogenesis of multiple sclerosis is venting toxic signaling molecules and managing antigen presentation. As for the antibodies themselves, the majority are not specific to myelin at all, yet their presence proves that a localized, autonomous autoimmune firefight is tearing through the brain. Statistically, if you find OCBs in a randomly drawn CSF sample, there is roughly a 65% probability that multiple sclerosis is driving the ignition.

By the way, antibodies targeted specifically at myelin do exist inside the brain; they just rarely manage to drift down into the CSF. The plasma cells manufactured to hunt myelin are surrounded by their target antigen literally on all sides. Their tracers lock onto their targets before they can ever wash out into the spinal fluid. Science calls this the "sponge effect": the moment an antibody rolls off the assembly line, it hits its target right outside the factory doors. Myelin fills the brain in massive volumes, functioning like a vacuum sponge that instantly absorbs every antibody engineered to dismantle it. Here is the ultimate irony: the single most critical laboratory analysis for exposing multiple sclerosis contains every imaginable antibody profile—except the ones actively tearing down your myelin sheaths.

Here is another detail proving how non-linear the immune grid can be: in about 5% of genuine MS cases, B-cells fail to establish dominant clonal lines, resulting in an absence of visible OCBs in the CSF analysis. In these tracks, the brain inflammation is termed "polyclonal," meaning hundreds of distinct B-cell families are participating, with each family manufacturing only a moderate volume of antibodies. On the laboratory gel, they spread out perfectly evenly without grouping into distinct, visible bands. Consequently, even an flawlessly executed spinal tap can yield a Type 1 synthesis profile (no bands) while multiple sclerosis continues to advance inside the brain along a polyclonal script. It is highly likely that this specific exception is what manufactured the widespread myth that lumbar punctures are completely useless.

Ultimately, a spinal tap is an incredibly informative analysis, but managing it comes with significant operational friction. The main hurdle isn't the test itself; it's how fast and carefully the courier hauls the sample to the lab matrix. If, after a random MRI throws up burning spots, your lumbar puncture returns a Type 1 synthesis profile (clean, no bands), you experience zero clinical symptoms, and a neurologist says, "Here are some interferons, they will help," know this: a second independent spinal tap will drastically cut down the probability of a "missed" diagnosis caused by a spoiled sample. Yes, it is painful, and yes, it is unpleasant—but is it worse than spending the rest of your life being treated for a disease you don't even have? Still, you cannot overlook the fact that you might sit among the 5% of people whose genuine MS operates along a polyclonal track. That said, as you can see from how the analysis works, generating a fake Type 2 profile (visible bands) without a massive laboratory blunder is practically impossible. But don't assume a Type 2 synthesis profile automatically means MS either; OCBs are not an exclusive hallmark of multiple sclerosis—they show up in other inflammatory CNS conditions as well.

In the context of multiple sclerosis, the metrics that matter are Type 1 and Type 2 synthesis profiles. Type 1 is completely normal; Type 2 is oligoclonal and highly characteristic of MS. In an effort to measure how well my fellow comrades in misfortune comprehend their lab results, I ran a poll: "Which spinal tap result belongs to a perfectly healthy person?" I offered three options: Type 1 synthesis, Type 2 synthesis, and "absence of synthesis." Spoiler alert: the last option doesn't exist in nature—a healthy profile is always labeled Type 1. Yet, 40% of the hundreds of patients who voted selected "absence of synthesis"—likely because they were convinced that Type 1 and Type 2 were both variants of an MS diagnosis, exactly as their neurologists told them. Less than half of Russian MS patients understand that a Type 1 synthesis profile means a negative test result.

Another poll asking, "Which synthesis type did your lumbar puncture reveal?" yielded these numbers: Type 2 synthesis — 30%; Type 1 synthesis — 20%; "never had a spinal tap" — 39%; other — 11%. Since Type 3 synthesis (Okonclonal bands showing up identically in both the CSF and blood serum) occurs in only 5 to 7% of genuine MS cases and is exceptionally rare in the wild, I frankly don't know what those who selected "other" had in mind. Between Type 1 and Type 2, the answers split 3:2, mapping to 60% and 40%, which explicitly proves that a massive slice of the polled population is actively treating a non-existent disease. It’s tough to calculate how the numbers would split in the "never had a tap" bracket, but I suspect the tilt toward Type 1 would be even more severe. It’s no surprise that a follow-up poll showed 65% of patients believe the spinal tap is non-informative—they don't know why; it’s simply what their doctors told them.

By the way, there is a myth floating around the internet that a spinal tap will only reveal a Type 2 profile several years after the disease starts—this is flat-out wrong. Once the first rogue T-cell breaches the brain, all it takes is a few chemical signals to draw B-cells into the hotspot. Once inside the brain tissue, B-cells activate and multiply; plasma cells debut continuously, and antibody production kicks off within the very first months of the disease. Within 3 to 6 months of the initial BBB breach, the volume of printed antibodies is high enough to construct visible oligoclonal bands on a gel matrix, yet actual clinical symptoms are still miles away—they typically manifest only 5 to 10 years after the demyelination process begins. Even if you are lucky enough to land on an MRI scanner before B-cells scale up their antibody factories, the budding hotspots will look like microscopic pinpricks—hardly enough for even an exceptionally sharp radiologist to confidently flag.

If someone were to open a specialized center in Russia where the CSF sample could be dropped onto a gradient matrix immediately after extraction and filtering, the accuracy of tracking oligoclonal bands would approach absolute perfection. In other words, to fix this diagnostic vulnerability, you simply need to haul the patients to the laboratory matrix, rather than hauling the biological material across town. The idea is simple, but no one is in any hurry to execute it. Why? I think it’s because the entire multiple sclerosis treatment market has long stabilized around MRI hotspots, and nobody wants to rock the boat. On top of that, it seems very few neurologists have ever bothered to look under the hood of the analysis to understand why it can return a "non-informative" result.

On Courses and the "Continuum" of Multiple Sclerosis

If you carefully read the section of the first chapter dedicated to the pathogenesis of multiple sclerosis, you should have realized that this disease has existed for as many years as humanity itself. The randomized assembly of lymphocyte receptors driven by V(D)J recombination emerged long before fish first crawled out of the water—at least 500 million years ago. Autoimmune glitches were bound to appear alongside this evolutionary innovation. The EBV virus, considered one of the chief triggers for MS today, is no newcomer either; it emerged about 12 million years ago. Honestly, it is hard to even imagine how ancient healers explained the symptoms of multiple sclerosis—likely attributing them to curses, witchcraft, and the wrath of angry gods. But that is all in the distant past: let’s fast forward to 1868, when Jean-Martin Charcot first described multiple sclerosis.

Charcot—who, by the way, was the first professor of neurology in history—saw MS patients far too late, when the symptoms of the disease could no longer be missed. This was roughly a century before the arrival of MRI scanners, so he could only see demyelination lesions during autopsies. All that was left for him was to observe the living sick. What he saw was a prolonged, monotonous, merciless decline—patients simply got worse and worse. He mapped out the chief "hallmarks" of the disease but could do absolutely nothing for the patients. Charcot didn't understand what was tearing his patients' brains apart, but he had no doubt that the disease was progressive and incurable—his observations confirmed that once multiple sclerosis starts, movement down this terrifying road goes in only one direction.

Charcot’s rigid concept began cracking at the seams by the 1920s. The disease was being caught at earlier stages, and doctors discovered to their amazement that after furious flare-ups, symptoms could completely vanish. Neurology plunged into a century-long abyss of terminological chaos. German neurologist Otfrid Foerster and his colleagues were the first to speak of the "intermittent" (interrupted) nature of the ailment, but no clear label was stamped on this phenomenon. By the mid-20th century, physicians began competing in linguistic creativity, racing to pack the unpredictability of MS into resonant tags. Medical charts were flooded with dozens of diagnoses: from "Marburg's acute malignant sclerosis," where a person burned out in months, to "McAlpine's benign sclerosis," where a patient went decades without developing a disability. Even in 1983, when Charles Poser's committee tried to bring order to the chaos, they only managed to standardize the diagnostic criteria, splitting MS into "definite" and "probable." The problem of disease courses remained untouched; scientists in the US flat-out didn't understand their colleagues in Europe. Pharmacology stalled: it was impossible to run clean clinical trials of drugs while researchers were still arguing over the names of an enemy that swapped masks at different stages of its life.

This linguistic schism dragged on until 1996, when the "International Advisory Committee on Clinical Trials of MS," spearheaded by Professor Fred Lublin, forced the world to speak a single language. Lublin took the path of hard-nosed pragmatism: his team blasted detailed questionnaires to 186 of the top neurologists across 18 countries. Aggregating and digitizing the opinions of the planet's brightest minds, the Committee hammered out a consensus that instantly buried dozens of subjective terms from the past. The world of multiple sclerosis was split into four isolated rooms. The first was assigned to relapsing-remitting multiple sclerosis (RRMS), with its distinct flare-ups and remissions. The second went to secondary-progressive multiple sclerosis (SPMS), where after a period of attacks, the disease launched a slow, uninterrupted advance. The third was handed to primary-progressive multiple sclerosis (PPMS), where decline marched from day one without any rollbacks. The fourth and rarest room was left for progressive-relapsing MS (PRMS). Fred Lublin brought an end to the global chaos: from that moment on, any doctor in Tokyo, Paris, or New York opened a chart and saw the exact same letters. Pharmaceutical companies received clear rules of the game and were finally able to launch targeted drug trials. No one suspected that this neat, orderly grid was nothing more than an illusion.